Loading
A phase 3 trial of Abarelix in Prostate cancer, run by Speciality European Pharma Limited, completed.
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT00841113 by Speciality European Pharma Limited, with 177 participants recorded, started 1999-01 and reaching its primary completion in 2001-02. Interventions recorded: Abarelix, Goserelin plus Bicalutamide. Conditions recorded: Prostate Cancer.
Linked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abarelix, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/